Published in
American Society of Hematology, Blood, p. blood-2018-04-840090
DOI: 10.1182/blood-2018-04-840090
Links
Tools
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
Journal article published in 2018 by
Matthieu Jestin,
Ygal Benhamou,
An-Sofie Schelpe 
,
Elien Roose ,
François Provôt,
Lionel Galicier,
Miguel Hié,
Claire Presne,
Pascale Poullin,
Alain Wynckel,
Samir Saheb,
Christophe Deligny,
Aude Servais,
Stéphane Girault,
Yahsou Delmas
and other authors.
,
Elien Roose ,
François Provôt,
Lionel Galicier,
Miguel Hié,
Claire Presne,
Pascale Poullin,
Alain Wynckel,
Samir Saheb,
Christophe Deligny,
Aude Servais,
Stéphane Girault,
Yahsou Delmas
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points TTP patients who display persistent and severe ADAMTS13 deficiency after remission have a relapse rate of 74% during long-term follow-up. Preemptive rituximab can decrease TTP relapses in 85% of patients with a favorable benefit-risk balance.